GlassScriptPhysician profile
Judith Lin
NPI 1538173091
$7,462.10
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,661 · 2020: $1,652 · 2021: $2,798 · 2022: $351.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $919.98 | 2019-2021 | |
| Amgen INC. | $754.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $718.49 | 2019-2021 | |
| Abbvie INC. | $609.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $429.31 | 2019-2021 | |
| Glaxosmithkline, LLC. | $404.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $342.85 | 2019-2021 | |
| Lilly USA, LLC | $328.38 | 2019-2022 | |
| Pfizer INC. | $289.61 | 2019-2021 | |
| Amarin Pharma, INC. | $264.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $261.72 | 2019-2021 | |
| Allergan, INC. | $187.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $143.41 | 2019-2021 | |
| Eisai INC. | $97.38 | 2019-2021 |
Show all 42 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.